(Total Views: 543)
Posted On: 03/08/2021 5:28:26 PM
Post# of 148899
FBCoach18 wrote:
Hindsight being what it is. I appreciate Dr. P's work early on with CYDY and proving what CYDY as a company seemed to understand where this molecule can help the public at large ia HIV, NASH, Cancer and so on, but I believe his throwing us under the bus on a poor design is easier said today knowing what we know now. Dr Rahman stated quite clearly that when the trial was designed in Feb. for the first shot in March or April that little was known and picking the primary endpoints was different then than they are now. I love NP's comment to Dr P's statement. Quote " Thank you for the comment" unquote. The tail will not wag the dog lol!
my response:
100% agree,Trial Design is profoundly critical.
However, the Trial was designed adequately enough to provide data that is adequate enough, for Janet Woodcock to issue an EUA, if only she hade courage adequate enough combined with integrity. I don't know which of those she lacks more?
Hindsight being what it is. I appreciate Dr. P's work early on with CYDY and proving what CYDY as a company seemed to understand where this molecule can help the public at large ia HIV, NASH, Cancer and so on, but I believe his throwing us under the bus on a poor design is easier said today knowing what we know now. Dr Rahman stated quite clearly that when the trial was designed in Feb. for the first shot in March or April that little was known and picking the primary endpoints was different then than they are now. I love NP's comment to Dr P's statement. Quote " Thank you for the comment" unquote. The tail will not wag the dog lol!
my response:
100% agree,Trial Design is profoundly critical.
However, the Trial was designed adequately enough to provide data that is adequate enough, for Janet Woodcock to issue an EUA, if only she hade courage adequate enough combined with integrity. I don't know which of those she lacks more?
(2)
(1)Scroll down for more posts ▼
